ArticleAmerican journal of translational research2023
A prognostic model based on the COL1A1-network in gastric cancer.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- Activin A-Targeted Therapy in Cancer: An Updated Review on Challenges and Opportunities in Clinical Translation.Current pharmaceutical design · 2026Review
- CircRNA CeRNA networks in gastric cancer highlight FAP/FNDC1 as potential prognostic and therapeutic targets.Discover oncology · 2025Article
- Insights into the Gene Expression Profile of Classical Hodgkin Lymphoma: A Study towards Discovery of Novel Therapeutic Targets.Molecules (Basel, Switzerland) · 2024Article
- Characterize molecular signatures and establish a prognostic signature of gastric cancer by integrating single-cell RNA sequencing and bulk RNA sequencing.Discover oncology · 2024Article
- Risk stratification in gastric cancer lung metastasis: Utilizing an overall survival nomogram and comparing it with previous staging.World journal of gastrointestinal surgery · 2024Article
- ASPORIN: A root of the matter in tumors and their host environment.Biochimica et biophysica acta. Reviews on cancer · 2024Review
- Epigenomic analysis of formalin-fixed paraffin-embedded samples by CUT&Tag.Nature communications · 2023Article
- Jian Yun Qing Hua Decoction inhibits malignant behaviors of gastric carcinoma cells via COL12A1 mediated ferroptosis signal pathway.Chinese medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is one of the most common malignancies worldwide with a poor prognosis due to the lack of early detection and effective treatments. As a biomarker, collagen type I alpha 1 (COL1A1) is often dysregulated in some cancer types. However, the expression profile of COL1A1 and functional mechanism in GC is still unclear.
methodsTo screen for the different expression genes of GC vs. adjacent tissues, an RNA-seq dataset containing 30 clinical samples and multi-omics datasets of 478 samples were obtained from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, respectively. Then the functional enrichment analysis and survival analysis of dysregulated genes were performed. Furthermore, through constructing the protein-protein interactive network, the function mode of COL1A1 was studied. Finally, a prognostic model was built by least absolute shrinkage and selection operator (LASSO) Cox algorithm to assess the clinical value of COL1A1-network.
resultsFirstly, a total of 89 different expression genes (58 down-regulated and 31 up-regulated) that appeared simultaneously in both GEO and TCGA datasets were detected and enriched in some functions regarding the extracellular matrix. However, only 12 genes were significantly correlative with overall survival of GC patients. Among them, ASPN, COL1A1, COL12A1, FNDC1, INHBA and MMP12 could form a network that might activate the epithelial-mesenchymal transition (EMT) pathway. Meanwhile, a prognostic model containing ASPN and INHBA was able to divide GC patients into 2 groups with different risks and predict 5-years survival accurately (AUC = 0.732, 95% CI (0.619, 0.845)).
conclusionCOL1A1 is up-regulated in GC and may result in a poor prognosis with a higher mRNA level. Moreover, the COL1A1-network may promote malignant metastasis via EMT pathway activation and act as a prognostic marker.
Indexed as
Identifiers
37056863PMC10086874W4365483440What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.